NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been assigned an average rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.50.

Separately, Weiss Ratings lowered shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.43 on Tuesday. The stock has a market capitalization of $16.12 million, a P/E ratio of -0.79 and a beta of 1.62. NeuroSense Therapeutics has a 52-week low of $0.25 and a 52-week high of $1.98. The stock’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $0.73.

Insiders Place Their Bets

In related news, CFO Or Eisenberg purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer owned 1,504,050 shares in the company, valued at $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Alon Ben-Noon acquired 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief executive officer owned 4,534,233 shares in the company, valued at $3,627,386.40. This trade represents a 5.84% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 27.40% of the company’s stock.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics in the third quarter worth about $26,000. Jane Street Group LLC bought a new position in NeuroSense Therapeutics in the 2nd quarter valued at $54,000. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics during the 2nd quarter valued at $56,160. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. 1.04% of the stock is currently owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.